Here are the DEF 14A proxy statements from Kairos Pharma, Ltd. (KAPA) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A DEF 14A covers the proxy statement, with executive pay and the shareholder votes, so if you follow KAPA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KAPA filings page.
Kairos Pharma, Ltd. is asking stockholders at its June 29, 2026 virtual annual meeting to elect four directors, ratify Weinberg & Company, P.A. as auditor, and approve several governance items. Proposals include authority for a reverse stock split at a ratio between 1:3 and 1:250 and an advisory vote on executive pay.
The company also seeks approval to add 5,000,000 shares to its 2023 Equity Incentive Plan and adopt an evergreen provision for an automatic 5% annual share increase for ten years. Stockholders of record on May 15, 2026, when 21,411,198 common shares were outstanding, may vote online, by phone, mail, or during the live webcast.